Literature DB >> 16807729

Population clinical pharmacology of children: modelling covariate effects.

Brian J Anderson1, Karel Allegaert, Nicholas H G Holford.   

Abstract

INTRODUCTION: Population modelling using mixed effects models provides a means to study variability in paediatric drug responses among individuals representative of those in whom the drug will be used clinically. DISCUSSIONS: Explanatory covariates explain the predictable part of the between-individual variability. Growth and development are two major aspects of children not seen in adults. These aspects can be investigated by using size and age as covariates. Problems attributable to co-linearity can be approached by using size as the first covariate. Size standardisation is achieved using allometric scaling, a mechanistic approach that has a strong theoretical and empirical basis. Age is used to describe the maturation of clearance. The quantitative models (linear, exponential, first-order, variable slope sigmoidal) used to describe this maturation process vary depending on the span of the ages under investigation. Measures of response are not always straightforward and can be more difficult to quantify in children.
CONCLUSION: Covariate investigation in children is improving the understanding of developmental aspects of drug disposition and effects in the paediatric population, ultimately leading to more effective use of medications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807729     DOI: 10.1007/s00431-006-0189-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  57 in total

Review 1.  Scaling for size: some implications for paediatric anaesthesia dosing.

Authors:  Brian J Anderson; George H Meakin
Journal:  Paediatr Anaesth       Date:  2002-03       Impact factor: 2.556

2.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

3.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

4.  Pharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients.

Authors:  Eiji Yukawa; Masayasu Satou; Toshiharu Nonaka; Miho Yukawa; Shigehiro Ohdo; Shun Higuchi; Takeshi Kuroda; Yoshinobu Goto
Journal:  J Clin Pharmacol       Date:  2002-01       Impact factor: 3.126

5.  Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity.

Authors:  K Allegaert; B J Anderson; R Verbesselt; A Debeer; J de Hoon; H Devlieger; J N Van Den Anker; D Tibboel
Journal:  Br J Anaesth       Date:  2005-06-10       Impact factor: 9.166

6.  Perioperative changes in alpha 1-acid glycoprotein concentrations in infants undergoing major surgery.

Authors:  P D Booker; C Taylor; G Saba
Journal:  Br J Anaesth       Date:  1996-03       Impact factor: 9.166

7.  Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.

Authors:  Brian J Anderson; Gerard Pons; Elisabeth Autret-Leca; Karel Allegaert; Eric Boccard
Journal:  Paediatr Anaesth       Date:  2005-04       Impact factor: 2.556

8.  Why do newborn infants have a high plasma creatinine?

Authors:  J P Guignard; A Drukker
Journal:  Pediatrics       Date:  1999-04       Impact factor: 7.124

9.  Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children.

Authors:  R D Brown; G L Kearns; J T Wilson
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

10.  A simple estimate of glomerular filtration rate in full-term infants during the first year of life.

Authors:  G J Schwartz; L G Feld; D J Langford
Journal:  J Pediatr       Date:  1984-06       Impact factor: 4.406

View more
  74 in total

1.  Bioavailability of inhaled fluticasone propionate via chambers/masks in young children.

Authors:  K Blake; R Mehta; T Spencer; R L Kunka; L Hendeles
Journal:  Eur Respir J       Date:  2011-09-20       Impact factor: 16.671

2.  A reduction in between subject variability is not mandatory for selecting a new covariate.

Authors:  Chakradhar V Lagishetty; Pavan Vajjah; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-06       Impact factor: 2.745

3.  Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

Authors:  Yasuhiro Tsuda; Shinji Tatami; Norio Yamamura; Yusuke Tadayasu; Akiko Sarashina; Karl-Heinz Liesenfeld; Alexander Staab; Hans-Günter Schäfer; Ichiro Ieiri; Shun Higuchi
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

4.  Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.

Authors:  Caroline Petit; Vincent Jullien; Adeline Samson; Jérémie Guedj; Jean-René Kiechel; Sarah Zohar; Emmanuelle Comets
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care.

Authors:  Karel Allegaert; Catherine Sherwin
Journal:  Eur J Pediatr       Date:  2016-01-07       Impact factor: 3.183

6.  Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.

Authors:  Maurice J Ahsman; Enno D Wildschut; Dick Tibboel; Ron A Mathot
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

7.  Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.

Authors:  Géraldine Pettersen; Mohamad-Samer Mouksassi; Yves Théorêt; Line Labbé; Christophe Faure; Bao Nguyen; Catherine Litalien
Journal:  Br J Clin Pharmacol       Date:  2008-10-23       Impact factor: 4.335

8.  Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Authors:  Alexander A Vinks; Ronald N van Rossem; Ron A A Mathôt; Harry G M Heijerman; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 9.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

10.  Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.

Authors:  Sílvia M Illamola; Helena Colom; J G Coen van Hasselt
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.